INmune Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Net Income	-30.01	-27.3	-30.34	-12.1	-7.68	-12.44	-0.83	-0.28
Share-Based Compensation	7.37	7.15	4.8	3.11	4.1	10	0.2	0
Other Operating Activities	10.66	-2.54	-2.96	0.04	-1.8	0.38	-0.13	-0.04
Operating Cash Flow	-11.98	-22.69	-28.5	-8.94	-5.38	-2.06	-0.76	-0.32
Acquisitions	0	0	-15	0	0	0	-0.1	0
Investing Cash Flow	0	0	-15	0	0	0	-0.1	0
Share Issuance / Repurchase	0.78	0.73	81.41	23.9	12.21	0.9	2.06	0.1
Debt Issued / Paid	-5	0	14.95	0	0	0	0	0.35
Financing Cash Flow	-4.23	0.73	96.36	23.9	12.21	0.9	2.06	0.45
Exchange Rate Effect	-0.1	-0.7	-0.01	0.02	-0.02	-0.03	0.03	-0
Net Cash Flow	-16.31	-22.66	52.84	14.97	6.81	-1.18	1.23	0.13
Free Cash Flow	-11.98	-22.69	-28.5	-8.94	-5.38	-2.06	-0.76	-0.32
Free Cash Flow Margin	-7729.03%	-6065.78%	-15748.07%	-81300.00%	-	-	-	-
Free Cash Flow Per Share	-0.67	-1.26	-1.77	-0.75	-0.52	-0.24	-0.12	-0.06

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).